Clinical Trial Update: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 trial evaluating NC410 in combination with pembrolizumab for advanced unresectable or metastatic solid tumors across multiple histologies, i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Endometrial Cancer
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Cancer
• Lung Cancer
• Ovarian Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• NC410

Snippet

Sponsor: NextCure, Inc. | Conditions: Advanced or Metastatic Solid Tumors, Microsatellite Instability Low | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING